Dr. Burke on a Study Investigating Obinutuzumab in Large B-Cell Lymphoma

John M. Burke, MD, discusses the GOYA study, a phase III study investigating obinutuzumab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma. Burke discussed the study during the American Society of Hematology (ASH) Annual Meeting.

In the lab, obinutuzumab (Gazyva) looks to have different properties that could make it, in theory, more effective that rituximab (Rituxan) in treating malignancies that express CD20, like large-cell lymphoma, Burke says.